Chang Chee-Jen, Chou Tse-Chih, Chang Chiung-Chih, Chen Ta-Fu, Hu Chaur-Jong, Fuh Jong-Ling, Wang Wenfu, Chen Chiung-Mei, Hsu Winco, Huang Chin-Chang
Graduate Institute of Clinical Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Department of Cardiovascular Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Alzheimers Dement (N Y). 2018 Jul 17;5:46-51. doi: 10.1016/j.trci.2018.06.013. eCollection 2019.
The objective of the study was to assess adherence and persistence of patients treated with rivastigmine versus donepezil.
Persistence was calculated as the time from the first prescription date of rivastigmine/donepezil until discontinuation/medication switch/end of available data, whichever occurred first. Adherence was calculated as proportion of days covered and medication possession ratio.
A majority of patients persisted on 4.5 and 6 mg of rivastigmine for 429 and 468 days, respectively, versus 443 and 441 days for patients receiving 5 and 10 mg of donepezil daily, respectively. Patients who initially received 1.5 mg of oral rivastigmine required a shorter time to reach a stable dose compared with those who initiated treatment at a higher dose of rivastigmine. Patients at a stable dose of 4.5 or 6 mg of rivastigmine were observed to persist longer than those at a lower dose of rivastigmine and donepezil.
Although results indicate significant difference in persistence between rivastigmine and donepezil groups, clinical significance remains undetermined.
本研究的目的是评估接受卡巴拉汀与多奈哌齐治疗的患者的依从性和持续性。
持续性计算为从卡巴拉汀/多奈哌齐的首次处方日期到停药/药物转换/可用数据结束的时间，以先发生者为准。依从性计算为覆盖天数的比例和药物持有率。
大多数患者分别持续服用4.5毫克和6毫克卡巴拉汀429天和468天，而接受每日5毫克和10毫克多奈哌齐治疗的患者分别持续443天和441天。与以较高剂量卡巴拉汀开始治疗的患者相比，最初接受1.5毫克口服卡巴拉汀的患者达到稳定剂量所需时间更短。观察到稳定剂量为4.5毫克或6毫克卡巴拉汀的患者比低剂量卡巴拉汀和多奈哌齐的患者持续时间更长。
虽然结果表明卡巴拉汀组和多奈哌齐组在持续性方面存在显著差异，但临床意义仍未确定。
